Chronic Myeloid Leukemia (CML)

Oncology
2
Pipeline Programs
3
Companies
4
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 2 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Novartis
NovartisBASEL, Switzerland
2 programs
1
1
ABL001/AsciminibPhase 2Small Molecule1 trial
Gleevec/GlivecPhase 11 trial
Active Trials
NCT01066468Terminated3
NCT06514534Recruiting20Est. Dec 2028
AB
AP BiosciencesTaiwan - Taipei
1 program
Collection of blood and bone marrowN/A1 trial
Active Trials
NCT03481868RecruitingEst. Feb 2026
Takeda
TakedaTOKYO, Japan
1 program
ponatinibN/ASmall Molecule1 trial
Active Trials
NCT01592136Approved For Marketing

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
NovartisABL001/Asciminib
NovartisGleevec/Glivec
AP BiosciencesCollection of blood and bone marrow

Clinical Trials (4)

Total enrollment: 23 patients across 4 trials

NCT06514534NovartisABL001/Asciminib

Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.

Start: Feb 2025Est. completion: Dec 202820 patients
Phase 2Recruiting
NCT01066468NovartisGleevec/Glivec

Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.

Start: Oct 20103 patients
Phase 1Terminated

Expanded Access Program of Ponatinib

N/AApproved For Marketing
NCT03481868AP BiosciencesCollection of blood and bone marrow

EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors

Start: Feb 2018Est. completion: Feb 2026
N/ARecruiting

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 actively recruiting trials targeting 23 patients
3 companies competing in this space